Curriculum Vitae

Publications

1. A latent sensitivity framework translates preclinical drug response to clinical combination efficacy. First author

   Schwerd-Kleine P, Wagner JP, Palmer AC. Submitted, Cancer Research.

2. Neuroendocrine transdifferentiation defines a monitorable and targetable therapy-escape state in HER2-positive breast cancer. Co-first author

   Schwerd-Kleine P*, Würth R*, Cheytan T*, et al. Under review, Cancer Discovery. (*equal contribution)

3. An in-depth single-cell and spatial map of inflammatory breast cancer reveals an immunosuppressive and inflammation-like microenvironment. First author

   Schwerd-Kleine P, et al. Manuscript.

4. Biopsy-derived organoids in personalised early breast cancer care. First author

   Schwerd-Kleine P, et al. Int. J. Cancer 2025;156(11):2200–2209. doi:10.1002/ijc.35386

5. Circulating tumor cell plasticity determines breast cancer therapy resistance via NRG1–HER3 signalling. Co-author

   Würth R, et al. Nature Cancer 2024. doi:10.1038/s43018-024-00882-2

6. Induction of a metabolic switch from glucose to ketone metabolism programs ketogenic diet–induced therapeutic vulnerability in lung cancer. Co-author

   Wu Y, et al. Cell Metabolism 2025;37:2233–2249.e9. doi:10.1016/j.cmet.2025.10.001